Results 241 to 250 of about 60,894 (286)

Re-evaluating the impact and cost-effectiveness of pneumococcal conjugate vaccine introduction in 112 low-income and middle-income countries in children younger than 5 years: a modelling study.

Lancet Glob Health
Chen C, Ang G, Akksilp K, Koh J, Scott JAG, Clark A, Jit M.   +6 more
europepmc   +1 more source

Evaluation of statistical models of carriage to predict the impact of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Nigeria

Adamu AL, Ojal J, Mburu C, Gallagher KE, Flasche S, Odeyemi K, Okoromah CA, Abubakar IS, Bello MM, Inem V, Karani A, Karia B, Akech D, Adetifa IM, Scott JAG.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era.

Clinical Infectious Diseases, 2020
BACKGROUND Introduction of pneumococcal conjugate vaccines (PCVs) has shown a marked reduction in the disease caused by vaccine serotypes in children providing herd protection to the elderly group.
S. de Miguel, Mirian Domenech, F. González-Camacho, Julio Sempere, D. Vicioso, J. Sanz, Luis García Comas, C. Ardanuy, A. Fenoll, J. Yuste   +9 more
semanticscholar   +1 more source

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

The Pediatric Infectious Disease Journal, 2000
Objective. To determine the efficacy, safety and immunogenicity of the heptavalent CRM197 pneumococcal conjugate vaccine against invasive disease caused by vaccine serotypes and to determine the effectiveness of this vaccine against clinical episodes of ...
S. Black, H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. Hansen, L. Elvin, K. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, K. Edwards   +16 more
semanticscholar   +1 more source

Pneumococcal conjugate vaccines

Immunology Letters, 1991
We have prepared conjugates of pneumococcal type 4 polysaccharides (PS4) or oligosaccharides to tetanus toxoid using the carbodiimide method. The use of a spacer, 6-aminohexanoic acid, resulted in higher incorporation of carrier protein. Conjugates contained up to 10% free polysaccharide, but no free protein.
Bart L. Haagmans, Ger T. Rijkers, Dolf Evenberg, Ben J.M. Zegers, Anne-Marie Tenbergen-Meekes, Jan Poolman, Carla C. A. M. Peeters   +6 more
openaire   +2 more sources

Conjugated Heptavalent Pneumococcal Vaccine

The Annals of Pharmacotherapy, 2002
OBJECTIVE: To review the immunogenicity, efficacy, and safety of the heptavalent conjugated pneumococcal vaccine (PCV7). DATA SOURCES: A MEDLINE search (1993–August 2001) of research limited to humans published in the English language was conducted. STUDY SELECTION: Findings from randomized, controlled, multicenter trials were reviewed.
Vinita B. Pai, John Erramouspe, Catherine A Heyneman   +2 more
openaire   +3 more sources

The pneumococcal protein conjugate vaccines

The Journal of Pediatrics, 2000
to develop the first licensed pneumococcal vaccine, consisting of 14 purified capsular polysaccharide antigens representing the most prevalent disease-associated serotypes. Coverage was improved by the addition of 9 more purified polysaccharide antigens, resulting in the currently licensed 23valent pneumococcal capsular polysaccharide vaccine.
Timothy R. Peters, Kathryn M. Edwards
openaire   +3 more sources

Pneumococcal conjugate vaccine

Current Opinion in Pediatrics, 2001
Pneumococcal infections account for a significant proportion of bacterial infections in infants and children. The growing threat from pneumococci resistant to penicillin and other antimicrobials has led to increased pressure for the development of an effective vaccine.
openaire   +2 more sources

The potential of pneumococcal conjugate vaccines for children

The Pediatric Infectious Disease Journal, 2002
In contrast to earlier pneumococcal vaccines, conjugate vaccines hold promise for reducing pneumococcal morbidity and mortality in infants and young children. The first commercially available conjugate vaccine formulation, which targets seven serotypes, was licensed in the US and other countries in 2000; this vaccine is now part of routine infant ...
Cynthia G, Whitney, Larry K, Pickering
openaire   +3 more sources